Clinical Trial Detail

NCT ID NCT01514864
Title Trial of Dasatinib in Subjects With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Bristol-Myers Squibb
Indications

lung non-small cell carcinoma

Therapies

Dasatinib

Age Groups: adult senior

Additional content available in CKB BOOST